|
Dear Colleagues:
As clinical trials are increasingly being conducted in emerging regions, Asia is quickly becoming a primary region for outsourcing clinical trials. China, in particular, is one of the most dominant countries for foreign-sponsored clinical research as a result of many factors. However, sponsors must overcome several barriers, among the largest of which are linguistic and cultural differences.
We have recently published an article in Pharma Focus Asia (issue 14) entitled
"China's Clinical Trial Boom: A look at linguistic and cultural considerations"
The article provides an overview of the current clinical research environment, as well as recommendations for overcoming linguistic and cultural barriers.
- What is the current regulatory approval process in China?
- What are the challenges in translating regulatory documents into Mandarin Chinese?
- How can foreign sponsors overcome the barriers?
We hope you take this opportunity to read the article and that it provides you with new and valuable information.
As a language service provider for over fifteen years, we are well aware of the importance of accurate, quality translation, especially in the translation of clinical trial documents. Our life science experts have translation experience in over one hundred languages, including Mandarin Chinese. Not only are they native speakers, they also know the importance of incorporating cultural context in the production of high quality, culturally-adapted translations.
| 
